Briefing.com hourly in play (r) paris france travel

• Asian markets saw a lack luster session with both Japan and China finishing the day just above the flat-line. The Shanghai was unable to sustain early gains but managed to pull of the paris france homes lows in the final hour to close in positive territory. On the contrary, the Nikkei opened lower and managed to grind its way higher to post a 0.1% gain on the day. This marked a 2-month high for Japan’s benchmark but relative strength was seen in the more defensive spaces.

• European bourses are trading marginally lower to begin the day. Corporate earnings are playing a role in the action today. Financials are modestly weaker following results from HSBC, which is down about 4% after releasing FY18 results. Consumer staple Danone is also lower by over 1% after the company reported a 4% decline in net income for FY18.

• Co completes another major milestone in its simplification programme with the announcement of the sale of its US K12 courseware business to Nexus Capital Management LP (Nexus) for headline consideration of $250m. Total proceeds comprise an initial cash payment of $25m and an unconditional vendor note for $225m expected to be repaid in three to seven years.

• Following the repayment of the vendor note, Pearson is entitled to 20% of all future cash flows to equity holders and 20% of net proceeds in the event the business is sold. This additional consideration has been pictures of paris massacre structured to provide Pearson with the potential to capture future upside in the US K12 courseware adoptions market over the coming years.

• Co announced that it has received a highly conditional unsolicited expression of interest from Canyon Capital Advisors and Platinum Equity Advisors, to acquire the Company for $12.50 per share in cash, which represents a premium of only 6.6% over Navient’s most recent closing price on February 15, 2019 of $11.73 per share and a discount of 2.8% to the one-year volume-weighted average price of $12.86 per share. Navient’s Board, in consultation with its financial and legal advisors, has carefully reviewed the expression of interest and unanimously determined that it substantially undervalues the Company and is not in the best interests of Navient or its stockholders. Therefore, Navient’s Board rejected the expression of interest.

A federal judge in the Southern District of New York on Feb. 15 ruled against Windstream Services, LLC, regarding the 2015 spinoff of certain telecommunications network assets into a real estate investment trust (REIT) and its agreements with bondholders. The company is continuing to evaluate its options, including post-trial motions and an appeal. The company currently expects to release the four-quarter and full-year 2018 financial results no later than March 18.

The FDA accepted the company’s New Drug Applications (NDAs) and granted Priority Review for entrectinib for the treatment of adult and paediatric patients with neurotrophic location of paris france tropomyosin receptor kinase (NTRK) fusion-positive, locally advanced or metastatic solid tumours who have either progressed following prior therapies or as an initial therapy when there are no acceptable standard therapies, and for the treatment of people with metastatic, ROS1-positive non-small cell lung cancer (NSCLC). The FDA is expected to make a decision on approval by 18 August paris france travel 2019.

• Study results demonstrated that investigators were able to develop an easy-to- use risk prediction tool to identify patients at high risk of developing respiratory compromise, a potentially life-threatening condition causing a progressive inability to breathe adequately. In addition, results showed that more than 40 percent of patients on the general care floor experienced OIRD, which is significantly higher than previously reported in clinical literature.

• Co announced presentation of the full results from the pivotal Phase 3 KEYNOTE-426 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Inlyta (axitinib), a tyrosine kinase inhibitor, for the first-line treatment of advanced renal cell carcinoma (RCC) at the 2019 Genitourinary Cancers Symposium (ASCO GU). These data were also simultaneously published in the New England Journal of Medicine. This is the first combination regimen to significantly improve overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) compared to sunitinib. Results were consistent across all IMDC subgroups, including favorable, intermediate and poor risk groups, and regardless of PD-L1 expression.

• Results of a phase I study: As of December 24, 2018, 12 advanced renal cell carcinoma patients were treated with telaglenastat plus cabozantinib and evaluable for response, including 10 clear cell patients, and two papillary patients. One hundred percent of evaluable patients experienced tumor shrinkage and disease control; this includes five patients who had a partial response and seven patients who had stable disease. In the clear cell patient population, the disease control rate was 100 percent and the response rate was 50 percent. Patients enrolled in the trial had advanced or metastatic disease and had received a median of three prior treatments, which included tyrosine kinase inhibitors, mTOR inhibitors, and checkpoint inhibitors. Patients were administered telaglenastat location of paris in france in oral doses that ranged from 600-800 mg twice a day in combination with a fixed oral dose of cabozantinib at 60 mg once a day.

• Co announced that a federal judge in the Southern District of New York ruled against one of its subsidiaries, Windstream Services, LLC, regarding the 2015 spinoff of certain telecommunications network assets into a real estate hotel d’angleterre paris france investment trust and its agreements with bondholders. The decision arose from challenges by Aurelius Capital Management and U.S. Bank National Association that the spinoff was invalid under the terms of those agreements.

• We are disappointed in, and frankly surprised by, the ruling and will be taking immediate steps to pursue all available options, including post-trial motions and an appeal. Additionally, we will work with our creditors on the next course of action. Windstream provides critical voice and data services to customers across the U.S. We remain committed to serving them and ensuring they realize the maximum benefit in transitioning to next-generation technology solutions and premium broadband services.

The stock repurchase authorization does not have an expiration date and the pace of repurchase activity will depend on factors such as Oracle’s working capital needs, cash requirements for acquisitions and dividend payments, debt repayment obligations or repurchases of Oracle’s debt, Oracle’s stock price, and economic and market conditions. The stock repurchases may be effected from time to time through open market purchases or pursuant to a Rule 10b5-1 plan.

• Earlier today, the Opposition Division of the European Patent Office revoked Immunex’s European Patent No. 2,990,420 in its entirety because the claims were invalid for insufficiency of disclosure. This follows a decision yesterday by the Patent Trial and Appeal Board of the USPTO to invalidate all 17 claims of Immunex’s U.S. Patent No. 8,679,487 as obvious. These decisions are subject to appeal by Immunex.

Scott Pittman will be joining Chaparral effective February 28, 2019, and will be appointed Chief Financial Officer and Executive Vice President of the Company effective March 16, 2019. Most recently, Mr. Pittman served as the Chief Financial Officer of Ursa Resources, an exploration and production company focused on unconventional resource development.

• Industrial production declined 0.6% in January (Briefing paris france weather in july.com consensus +0.2%) following a downwardly revised 0.1% increase (from 0.3%) in December. The January downturn was driven by a large drop in motor vehicle assemblies. The capacity utilization rate fell to 78.2% (Briefing.com consensus 78.8%) from an upwardly revised 78.8% (from 78.7%).

Results for the fourth quarter of 2018 fell short of management’s expectations in large part due to incentives and performance of its two largest brands, [ BMWYY] and Honda [ HMC] , which represent ~40% of the Company’s store level volume and profitability. In particular, we did not experience the fourth quarter increase in profitability from our BMW stores that we have historically experienced and our paris france weather 10 day volume expectations for both brands were also not achieved. Despite the overall market declining for these brands, our BMW and Honda stores collectively maintained their unit share of the local markets in which the stores operate. We are confident that these brands, which have performed well in years past, will return to higher levels of performance in the future, but did not anticipate the declines experienced in the fourth quarter of 2018.